Myeloma Trial, Recruiting (NCT07342179)

Myeloma Trial, Recruiting NCT07342179 Sponsor: Poitiers University Hospital Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT07342179 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 or older
People who have been diagnosed with Multiple Myeloma, as defined by international medical guidelines
People who are about to receive a type of treatment called CAR-T cell therapy, approved and authorised for use in France

Who may not be able to join:

People whose physical or mental health is severely affected in a way that, in the opinion of the trial investigator, may make it difficult for them to follow the study requirements
People who are currently taking part in another clinical study that has an active exclusion period preventing them from joining additional studies
People who fall into certain protected categories, including those under 18, pregnant or breastfeeding women, people whose freedom has been restricted by a legal or administrative decision, people living in a healthcare or social care facility, adults under legal guardianship, or people in emergency situations

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0033549444201

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07342179

Sponsor: Poitiers University Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Myeloma

Trial contact: 0033549444201

More information: https://clinicaltrials.gov/study/NCT07342179

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 or older
People who have been diagnosed with Multiple Myeloma, as defined by international medical guidelines
People who are about to receive a type of treatment called CAR-T cell therapy, approved and authorised for use in France

Who may not be able to join:

People whose physical or mental health is severely affected in a way that, in the opinion of the trial investigator, may make it difficult for them to follow the study requirements
People who are currently taking part in another clinical study that has an active exclusion period preventing them from joining additional studies
People who fall into certain protected categories, including those under 18, pregnant or breastfeeding women, people whose freedom has been restricted by a legal or administrative decision, people living in a healthcare or social care facility, adults under legal guardianship, or people in emergency situations

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Poitiers University Hospital

Registry

ClinicalTrials.gov

Start date

13 February 2026

Est. completion

3 October 2032

Where this trial is recruiting

🇫🇷 France

Primary endpoints

TCF-1 transcription factor (MFI) expression level in circulating CD3+ T cells; TCF-1 transcription factor (MFI) expression level in correlation with the depth of the patient's response as defined by international guidelines (IMS/IMWG criteria)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov